Astellas Pharma Inc. (OTCMKTS:ALPMY - Get Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $9.76 and traded as low as $9.53. Astellas Pharma shares last traded at $9.53, with a volume of 211,118 shares traded.
Astellas Pharma Stock Performance
The company's 50-day moving average price is $9.76 and its 200 day moving average price is $10.92. The stock has a market capitalization of $17.25 billion, a PE ratio of -43.32 and a beta of 0.34. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.86 and a current ratio of 1.10.
Astellas Pharma (OTCMKTS:ALPMY - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The company reported $0.30 EPS for the quarter. Astellas Pharma had a negative net margin of 3.10% and a positive return on equity of 13.48%. On average, equities research analysts expect that Astellas Pharma Inc. will post 0.58 earnings per share for the current fiscal year.
About Astellas Pharma
(
Get Free Report)
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Astellas Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astellas Pharma wasn't on the list.
While Astellas Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
